1

Effectiveness of one dose of killed oral cholera vaccine in an endemic 1

community in the Democratic Republic of the Congo: A matched case-control 2

3 study

- Espoir Bwenge Malembaka, MD PhD^{1,2}, Patrick Musole Bugeme, MD^{1,2}, Chloe Hutchins, PhD³, 4
- Hanmeng Xu, MHS¹, Juan Dent Hulse, ScM¹, Maya N. Demby, BSc¹, Karin Gallandat, PhD³, 5
- Jaime Mufitini Saidi, BSc⁴, Baron Bashige Rumedeka, BSc^{1,4}, Moïse Itongwa, BSc¹, Esperance 6
- Tshiwedi-Tsilabia, MSc⁵, Faida Kitoga, MSc⁵, Tavia Bodisa-Matamu, MD⁵, Hugo Kavunga-7
- Membo, MD PhD^{5,6}, Justin Bengehya, MPH⁷, Jean-Claude Kulondwa, MD⁷, Amanda K Debes, 8
- 9
- PhD⁸, Nagède Taty, MD⁹, Elizabeth C. Lee, PhD¹, Octavie Lunguya MD PhD^{6,10}, Prof. Justin Lessler, PhD^{1,11,12}, Daniel T Leung, MD^{13,14}, Oliver Cumming, MSc³, Placide Welo Okitayemba, MD⁹, Daniel Mukadi-Bamuleka, MD PhD^{5,6,10}, Jackie Knee, PhD³, Andrew S Azman, PhD^{1,15,16*} 10 11
- ¹Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA 12
- 13 ²Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu,
- Bukavu, Democratic Republic of the Congo 14
- 15 ³Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK
- ⁴*Ministère de la Santé Publique, Zone de Santé d'Uvira, Democratic Republic of Congo* 16
- ⁵*Rodolphe Merieux INRB-Goma Laboratory, Goma, North-Kivu, Democratic Republic of the* 17 18 Congo
- 19 ⁶Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the 20 Congo
- 21
- ⁷Ministère de la Santé Publique, Hygiène et Prévention, Division Provinciale de la Santé 22 Publique du Sud-Kivu, Democratic Republic of the Congo 23
- 24 ⁸Department of International Health, Johns Hopkins University, Baltimore, MD 21205, USA
- 25 ⁹PNECHOL-MD, Community IMCI, Ministry of Health, Democratic Republic of the Congo
- 26 ¹⁰Service of Microbiology, Department of Medical Biology, University of Kinshasa, Kinshasa, 27 Democratic Republic of the Congo
- 28 ¹¹University of North Carolina Population Center, University of North Carolina at Chapel Hill, 29 Chapel Hill, NC. USA
- ¹²Department of Epidemiology, Gillings School of Global Public Health, University of North 30
- 31 Carolina at Chapel Hill, Chapel Hill, NC, USA
- 32 ¹³Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, Utah, 33 USA

- 34 ¹⁴Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake
- 35 City, Utah, USA
- 37 ¹⁵Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,
- 38 Switzerland
- ¹⁶Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva,
 Switzerland
- 41 * Correspondence to:
- 42 Dr Andrew S Azman,
- 43 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
- 44 Johns Hopkins University, Baltimore, MD 21205, USA
- 45 <u>azman@jhu.edu</u>

3

75 Abstract

76 Background

- A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than
- the standard two-dose regimen. There is limited evidence on single-dose protection, particularly
- in children. In 2020, a mass vaccination campaign resulting in largely single dose coverage, was
- 80 conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo. We
- 81 examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus[®] in this
- 82 high-burden setting.

83 Methods

- 84 We recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-
- 85 matched community controls during two distinct periods after mass vaccination, October 2021 to
- 86 March 2022 (12–17 months post-vaccination) and October 2022 to October 2023 (24–36 months
- 87 post-vaccination). The odds of vaccination in cases and controls were contrasted in conditional
- 88 logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.

89 Findings

- 90 We enrolled 658 confirmed cases and 2,274 matched controls during the two study periods with
- 91 15.0% of cases being under five years old at the time of vaccination. The adjusted single-dose
- 92 VE was 52.7% (95% CI: 31.4–67.4) 12–17 months post-vaccination and 45.5% (95% CI: 25.8–
- 93 60.0) 24–36 months post-vaccination. While protection in the first 12–17 months post-
- 94 vaccination was similar for 1–4-year-olds and older individuals, over the third year post-
- 95 vaccination the estimate of protection in 1–4 year-olds (adjusted VE 33·1%; 95% CI: -30·0–65·6)
- 96 appeared to wane with confidence intervals spanning the null.

97 Interpretation

- 98 A single-dose of Euvichol-Plus[®] provided substantial protection against medically attended
- 99 cholera for at least 36 months post-vaccination in this cholera endemic setting. While our
- 100 evidence provides support for comparable levels of protection in young children and others in the
- 101 short-term, protection among young children may wane significantly by the third year after
- 102 vaccination.
- 103 Funding
- 104 Wellcome Trust and Gavi (GAVI-RFP-2019-062).
- 105
- 106

4

Research in context 107

108 Evidence before this study

109

110 In late 2022, due to increasing demand for killed, whole-cell, oral cholera vaccines (kOCV) 111 and limited production capacity, the International Coordinating Group (the organization 112 managing emergency stocks of kOCVs) changed policy to deploy single-dose, rather than the 113 standard two-dose regimen, for emergency vaccination campaigns. This decision was in line with 114 WHO guidance on the use of a single dose in outbreaks, where short-term protection is key. 115 However, this recommendation is based on a limited number of clinical studies with short-term 116 follow-up. There is also limited evidence on the magnitude and duration of protection conferred 117 by a single dose of kOCV, particularly in children under five years of age.

118

119 We searched PubMed for randomized trials and observational studies published in English

120 before November 1, 2023, that reported estimates of protection conferred by a single dose of

- 121 kOCV, using the term "(effectiveness OR efficacy) AND cholera* AND vaccine". We found no
- published studies estimating the effectiveness of a single dose of Euvichol-Plus[®], and only one 122
- 123 study reporting two-dose effectiveness. Despite this paucity of evidence, this is the only vaccine
- 124 currently available in the global stockpile. To date, there has been one randomized trial
- 125 conducted in Bangladesh between 2014 and 2016, and seven observational studies conducted
- 126 between 2009 and 2016 in Guinea, Haiti, India, Malawi, Sudan, Zambia and Zanzibar, reporting
- 127 effectiveness estimates of a single dose of the current generation of kOCV. Aside from the trial
- 128 in Bangladesh, all estimates were based on secondary analyses that the studies were not powered
- 129 to estimate. The Bangladesh trial is the only study to date that provides an age-stratified estimate
- 130 of single-dose protection, and while it found an overall protective efficacy of 62% (95% CI: 43-
- 131 75) during the 2-year follow up for individuals aged five years or older, it found no significant
- protection conferred by the Shanchol kOCV (a bioequivalent of Euvichol-Plus[®]) for individuals 132
- under five years of age (protective efficacy: -44%, 95% CI -220 to 35). Four of the seven 133
- 134 observational studies provide single-dose vaccine effectiveness (VE) estimates only during the
- 135 first 12 months post-vaccination with estimates ranging from 43% (95% CI -84-82) in Guinea to
- 136 93% (95% CI 69-98) in Haiti. The three other observational studies providing a single dose VE
- 137 estimate between 12-30 months post-vaccination were unable to demonstrate statistically
- 138 significant protection conferred by kOCV, with estimates ranging between 32.5% (95% CI -
- 139 318.0-89.1) in India and 40% (95% CI -31-73) in Haiti. No vaccine protection estimates have
- 140 been published from the two identified cholera endemic foci in Africa, the Democratic Republic
- 141 of the Congo and Nigeria.

142 Added value of this study

- In this vaccine effectiveness study, we show that a single dose of Euvichol-Plus[®] vaccine can 143
- 144 provide significant protection against medically attended cholera for up to 36 months
- 145 after vaccination in a cholera endemic setting in Africa, though protection in children under five
- 146 years old remains unclear. These estimates help fill critical gaps in our understanding of the
- 147 magnitude and duration of protection from a single dose of the most widely used kOCV,
- Euvichol-Plus[®] and is one of only a few studies to measure protection in an endemic setting in 148
- 149 Africa.
- 150 Implications of all the available evidence

5

- 151 The corpus of available evidence suggests that use of a single dose of kOCV in
- 152 emergency situations where cholera is endemic, like Uvira, is justified and that providing a
- second dose within the first 12-24 months post-vaccination may only provide marginal benefit to
- 154 the general population. However, more evidence and analyses are needed to weigh the costs and
- 155 benefits of tailored vaccination approaches for those under five years old, including possibility of
- 156 providing a second dose at an earlier timepoint.
- 157

6

159 Introduction

- 160 Safe water, sanitation, and hygiene (WASH) is the cornerstone of cholera prevention and control.
- 161 While universal access to safely-managed WASH services remains the ultimate priority, this is
- 162 likely a distant prospect.¹ Killed whole-cell oral cholera vaccine (kOCV) is an effective short-
- 163 term intervention to reduce cholera risk in high-burden settings and is a key component of the
- 164 global roadmap to end cholera.² kOCVs are typically delivered as a two-dose regimen that
- 165 provides protection for at least three years.^{3,4} In a meta-analysis of kOCV protection, estimated
- 166 two-dose efficacy was 58% (95% CI: 42 to 69), over an average of 28 months post-vaccination.
- 167 Lower protection was noted among young children.³
- 168 The Euvichol-Plus[®] vaccine (Eubiologics, Seoul, Republic of Korea) is currently the only WHO-
- 169 prequalified kOCV manufactured and included in the global stockpile after the Shanchol®
- 170 (Shantha Biotechnics, Hyderabad, India) ceased production in 2023.⁵ Euvichol-Plus[®] is
- 171 considered a bioequivalent of Shanchol[®].⁶ Almost all evidence of kOCV clinical protection is
- based on the studies carried out on Shanchol[®],^{7–9} although one observational study explored the
- 173 protection conferred by a Euvichol-Plus[®] two-dose regimen.¹⁰
- 174 Demand for kOCVs outstripped the global supply in 2022, with only 33 million doses distributed
- 175 out of the 72 million requested.¹¹ In late 2022, the International Coordinating Group, which
- 176 manages the global emergency stockpile for cholera vaccines, suspended the provision of the
- 177 standard two-dose regimen in emergency vaccination campaigns, replacing it with a single-dose
- 178 regimen due to limited vaccine supply.¹² However, there are limited data on the protection
- 179 offered by one dose of kOCV over extended periods (>12 months) or among children 1-4 years
- 180 old.
- 181 Only a few studies have estimated single-dose protection in the general population, with point
- 182 estimates suggesting short-term protection up to 16 months after vaccination in Haiti, though
- 183 with large uncertainty. ^{7–9,13–16} A randomized trial in Bangladesh, the only study to provide age-
- 184 stratified estimates of single-dose protection, suggested that Shanchol[®] conferred no protection
- 185 in 1-4 year-olds in the first six months post-vaccination, despite significant protection in older
- 186 individuals for at least two years.^{17,18}
- 187 In late 2020, the Ministry of Health of the Democratic Republic of the Congo (DRC) conducted
- 188 a mass vaccination campaign of Euvichol-Plus[®] in the city of Uvira in the South Kivu province.
- 189 The estimated coverage of the vaccination campaigns was low, and as most vaccinated
- 190 individuals reported receiving only one dose, we assessed effectiveness of a single dose of
- 191 kOCV during outbreaks that occurred 12-17 and 24-36 months after vaccination.

192 Study design, setting and vaccination campaigns

- 193 We conducted a matched case-control study in Uvira, a city of approximately 280,000
- 194 inhabitants on the northwestern shore of Lake Tanganyika with sporadic armed conflict, socio-

7

political instability, and population displacement. Cholera cases are detected year-round in Uvira since 1978, often with distinct seasonal peaks and notable historical outbreaks.^{19,20} Household surveys conducted in 2016/17 in Uvira indicated surface water as the main drinking water source for 37.2% of households,²¹ and in areas close to the rivers and with the lowest tap water availability, >80% of households use drinking water contaminated with *Escherichia coli*.²² The same surveys estimated that about half (48.2%) of the population relied exclusively on tap water

- for drinking needs 21 , and a recent study showed that between 2017 and 2021, the water service
- 202 quality remained suboptimal, or deteriorated in many parts of the city. $^{23 20}$
- 203 In April 2020, severe flooding caused at least 54 deaths, the displacement of approximately
- 204 80,000 people, and substantial damage to housing and WASH infrastructure in Uvira, prompting
- 205 the Ministry of Health to conduct emergency cholera vaccination campaigns.²⁴ Vaccination took
- 206 place in two rounds, from 29 July to 8 August and 28 September to 05 October 2020 targeting all
- 207 individuals in Uvira one year and older. The campaigns included door-to-door vaccination for
- 208 five days, followed by vaccination offered through health facilities. While two rounds of
- 209 vaccination were implemented, in a representative household survey we conducted 11 months
- after vaccination, 23% (95% CI: 20-27%) of the participants reported receiving two doses of the
- 211 vaccine and 32% (95% CI: 38-36%) reported receiving one dose. No kOCV has been
- administered in this population between these campaigns and the end of our study period, 18
- 213 October 2023.

214 Clinical cholera surveillance system in Uvira

215 Our study is based on enhanced clinical surveillance of cholera implemented at the two official 216 health facilities designated to treat cholera patients in Uvira, the cholera treatment centre at the 217 Uvira General Referral Hospital and the cholera treatment unit at the Kalundu CEPAC health 218 centre (henceforth, "CTCs"). We attempted to identify and recruit all patients at least 12 months 219 old with acute watery diarrhoea within the 24 hours prior to the admission to the CTCs (referred 220 to as 'suspected cholera'). Trained healthcare staff collected rectal swabs and stools from 221 participants. Rectal swabs were enriched in alkaline peptone water (APW) for 6-18 hours 222 depending on patient admission time. Specimens were tested for V. cholerae by rapid diagnostic 223 tests (RDTs) onsite, and by culture using standard methods (Appendix) at either an in-country 224 reference laboratory, the Laboratoire Rodolphe Mérieux de l'Institut National de Recherche 225 Biomédicale (INRB), in Goma (from October 2021 to September 2022), or at the onsite study 226 laboratory (from September 2022 onward). As PCR for V. cholerae O1 was not available at 227 either study laboratory in DRC, we shipped stool specimens (stool spotted on dry filter papers) 228 for cases enrolled between October 14, 2021 and May 04, 2022 to Johns Hopkins University for

229 PCR detection of toxigenic V. cholerae O1 following published methods.²⁵

230 Selection of cases and controls

8

Two cholera outbreaks occurred after mass vaccination, and we recruited cases during each

- outbreak, forming two distinct study periods (Figure 1). From 21 November 2022 to 24 January
- 233 2023, we retrospectively recruited controls for patients admitted to CTCs during the first
- outbreak (14 October 2021 to 10 March 2022), approximately 12-17 months after the second
- round of mass vaccination campaigns (Study Period 1). Between 17 October 2022 and 18
- October 2023, we recruited controls for cases as they were admitted to the CTCs, 24-36 months
- after vaccination (Study Period 2).
- 238 Study Period 1 (SP1) included all consenting suspected cases who were at least 12 months old
- during the vaccination campaigns, living in Uvira for the two weeks prior to admission to the
- 240 CTC and during the 2020 vaccination campaigns, and who tested positive for cholera by culture
- and/or PCR. We attempted to recruit four controls per case, using high-resolution satellite
 imagery (Appendix) to identify potential control households on the same avenue (smallest
- administrative unit in Uvira) as the case household. Control households were then selected by
- 243 administrative unit in Uvira) as the case household. Control households were then selected by 244 simple random spatial sampling of digitized residential structures. Controls were eligible for
- enrollment if: (1) they matched the case age group (1-4, 5-9, 10-19, 20-39, 40-59 or \geq 60 years
- 245 enforment II. (1) they matched the case age group (1-4, 5-9, 10-19, 20-39, 40-39 of \geq 00 years 246 old) and sex, (2) had not been admitted for acute watery diarrhoea or cholera in the three years
- prior to the case admission, (3) were living in Uvira in the two weeks prior to case admission, (4)
- were living in Uvira at the time of the 2020 kOCV campaign and were eligible to be vaccinated,
- and (5) none of their household members reported being admitted to a formal health facility (as
- 250 opposed to pharmacies, prayer homes or traditional healers) for acute watery diarrhoea or cholera
- 251 in the four weeks prior to case admission (Table S1).
- 252 During Study Period 2 (SP2), the case definition included the same age and residence criteria as
- in SP1, but cases had to test positive with both APW-enriched rapid diagnostic test (RDT) and culture (performed at the onsite laboratory). We used enriched RDT results to help prioritize
- control recruitment due to limited human resources during the outbreak. In contrast to SP1, we
- conducted a home visit within three days of hospital discharge to investigate the living and
- 257 WASH conditions in each case's household and ascertain the vaccination status outside the
- 258 hospital environment (as done with the controls). We excluded patients who died during
- 259 hospitalization and those whose residence could not be found during home visits. As in SP1, four
- 260 neighborhood controls were recruited from four randomly selected households near the case
- 261 household, though during this study period we selected households using the 'right-hand' rule
- 262 (Appendix). In addition to the recruitment criteria used in SP1, controls were eligible for
- enrolment in SP2 if their household matched that of the case by size (≤ 5 individuals, 6-10
- individuals, and >10 individuals) and had at least one child below five years of age when the
- case household had one.

266 Vaccination status ascertainment and potential confounding variables

- 267 Study staff administered structured questionnaires to all cases and controls (or their
- 268 parent/guardian) to capture demographics, household conditions, potential confounding variables

9

269 and vaccination status. Before asking each case or control whether they were vaccinated, study 270 staff showed them photos of the vaccine vials and of someone taking the vaccine, in addition to 271 explaining when and how the vaccines were delivered in Uvira, and how these may differ from 272 other campaigns and routine vaccines. Participants reporting vaccination were asked the number 273 of doses and when and where each one was taken. We also used vaccination cards to verify the 274 vaccination status whenever possible. In SP1, vaccine-related questions were asked to cases in 275 the clinic and in SP2 they were asked both in the clinic and a subsequent home visit. Any 276 differences in the vaccination status reporting between the clinic and household interviews were 277 solved through a third interview at the case's household followed by a review of the data, 278 discussion, and consensus within the study team. We identified potential confounders based on a 279 causal directed acyclic graph developed before the start of the study and attempted to measure 280 these through the interviews.

281 Statistical analyses

282 The characteristics of case and control participants were compared using the standardized mean 283 difference (SMD), which is the absolute difference in mean values of a variable between cases 284 and controls divided by the pooled standard deviation. In addition, we calculated p-values from 285 univariate conditional logistic regression models with case-control status as the dependent 286 variable. In the primary analysis, we compared the odds of being vaccinated with a single kOCV 287 dose between cases and controls using conditional logistic regression models. Those reporting to 288 have received 2 or more doses were dropped from the primary analyses. The vaccine 289 effectiveness (VE) was calculated as one minus the estimated odds ratio of having received a 290 single dose of vaccine, between cases and controls. To produce consistent age-group specific and 291 overall estimates of effectiveness across all ages, the conditional logistic regression model 292 included an interaction term for age group $(1-4 \text{ vs.} \ge 5)$ and the vaccination status. We derived the overall VE estimate based on a linear combination of parameters from the two age groups, 293 weighted by the proportion of cases within each, and estimated simultaneous confidence 294 intervals with the *ghlt* function in the *multcomp* R package.²⁶ For continuous variables, we 295 296 explored models using polynomials and restricted cubic splines, and compared them using 297 Akaike Information Criterion (AIC). For combined estimates (SP1/2) and those from SP1, we 298 incorporated age as a continuous variable, separately by the two age groups (with a quadratic 299 term for the age group \geq 5 years), to adjust for potential confounding. For SP2, estimates were 300 adjusted for a set of potential confounders including a quadratic term for age, a cubic term for 301 household size, household wealth index (as a continuous variable) derived from a principal 302 component analysis of household assets ownership (Appendix), type of sanitation facility, 303 whether the participant used a toilet shared by multiple households compared to using a private 304 toilet, drinking water sources, and availability of a hand washing facility and soap. We also fit 305 three alternative models with different sets of covariates to assess the robustness of the estimates 306 (Appendix). In a secondary analysis, we estimated the VE for at least one dose and two doses of 307 kOCV compared to the unvaccinated group. While we primarily relied on point estimates and

10

- 308 95% confidence intervals (CI) to assess the weight of evidence, we considered p-values
- 309 statistically significant when they were less than 0.05. Analyses were performed in R (version
- 310 4.3.1).

311 Ethical considerations

- 312 Ethical approvals were obtained from Institutional Review Boards of the Johns Hopkins
- 313 Bloomberg School of Public Health (IRB00015785), the London School of Hygiene & Tropical
- 314 Medicine (25365) and the École de Santé Publique at the University of Kinshasa
- 315 (ESP/CE/65/2021). Written informed consent was obtained from all participants ≥ 18 years, with
- 316 written assent from those <18 years in addition to written consent from their parent/guardian.

317 **Role of the funding source**

- 318 The funders of the study had no role in study design, data analysis, interpretation, preparation of
- 319 this manuscript, or the decision to publish.

320 **Results**

321 Cholera incidence in Uvira and recruitment of study participants

322

323 We recruited 658 unique confirmed cholera cases and 2,274 matched controls during the two

324 study periods (Figure 1), with 61.1% of cases enrolled in the second period. The median age of

325 participants at the time of the vaccination campaigns was 14.9 (interquartile range 6.3, 33.8)

326 years and 15.1% were under five years old (Table 1). Almost sixty-two percent of cases were

327 recorded as severely dehydrated on admission. Cases were significantly older during the first

328 study period compared to the second period (p=0.005), though they all had similar dehydration

329 status (Table S2). Of the 537 culture positive isolates, 390 (72.6%) were serotype Ogawa, the

rest were Inaba, including 19.3% (n=26/135) Inaba in SP1 and 30.1% (n = 121/402) Inaba in SP2.



Figure 1. Number of cholera cases admitted to cholera treatment facilities in Uvira. Panels A (Study Period 1) and B (Study Period 2) illustrate the cumulative number of confirmed cases in each study period by neighborhood (avenue) across the city, with the locations of the two health facilities where patients were recruited shown as dots. There were 14 cases living in neighboring communities outside the city boundaries that were included in Study Period 2. The second outbreak (Study Period 2) started in the northern part of the city and spread to a refugee camp where many residents were admitted to the CTC but not included in the study as they were not living in Uvira at the time of vaccination. Panel C illustrates the epidemic curve of suspected and confirmed cholera cases admitted to the cholera treatment center (CTC) at the Uvira General Referral Hospital and the cholera treatment unit (CTU) at the Kalundu CEPAC health center. Cholera was confirmed by culture or PCR (Study Period 1), or by APW-enriched RDT and culture (Study Period 2). Among the 183 suspected cases that were detected before SP1 (in grey), 146 (79·8) were tested for *Vibrio cholerae* O1 by enriched RDT with 37 (25·3%) testing positive.

346 Overall, 20.2% of cases reported receiving one dose of kOCV and 68.7% were unvaccinated. In

347 comparison, 31.6% of matched controls reported receiving a single dose of kOCV and 56.3%

- 348 were unvaccinated. Only 13.6% of vaccinated participants were able to show a vaccination card
- 349 and 11.9% reported having received two doses of the vaccine (Table 1).
- 350



- 351 352 Figure 2. Flow chart of participant recruitment. Cases with unavailable culture results are those
- 353 for which 1) suspected colonies were isolated, 2) with positive oxidase test at the field
- 354 laboratory, 3) missing agglutination results due to an antiserum stockout, 4) and/or in which
- 355 attempts to revitalize Vibrio cholerae O1 strains at the reference laboratory in Goma were 356 unsuccessful.
- 357
- 358
- 359

13

360	Table 1. Characteristics of	participants by c	ase and control status.
500	1 abic 1. Characteristics of	par incipantis by c	use and control statu

Characteristic	Overall,	Cases,	Controls,	P value	SMD
	N = 2,932	N = 658	N = 2,274		
Age at vaccination,	14.9 (6.3,	14.1 (6.0, 33.8)	15.1 (6.4,	0.0019	0.005
median (IQR)	33.8)		33.7)		
Age group at					0.122
vaccination (years)					
1-4	443 (15.1%)	99 (15.0%)	344 (15.1%)	Reference	
5-9	552 (18.8%)	146 (22.2%)	406 (17.9%)	0.0080	
10-19	764 (26.1%)	159 (24.2%)	605 (26.6%)	0.7183	
20-39	606 (20.7%)	124 (18.8%)	482 (21.2%)	0.8436	
40-59	401 (13.7%)	91 (13.8%)	310 (13.6%)	0.4146	
≥60	166 (5.7%)	39 (5.9%)	127 (5.6%)	0.4495	
Sex					0.001
Female	1,503	337 (51.2%)	1,166 (51.3%)	Reference	
	(51.3%)				
Male	1,429	321 (48.8%)	1,108 (48.7%)	0.8577	
	(48.7%)				
Vaccination status					0.277
Not Vaccinated	1,732	452 (68.7%)	1,280 (56.3%)	Reference	
	(59.1%)				
One Dose	851 (29.0%)	133 (20.2%)	718 (31.6%)	< 0.0001	
Two Doses	349 (11.9%)	73 (11.1%)	276 (12.1%)	0.0110	
Vaccination card	163 (13.6%)	29 (14.1%)	134 (13.5%)	0.1092	0.017
available					

361 P values are obtained from univariable conditional logistic regression models.

362 Additional data on socio-demographic and household characteristics were collected in SP2

363 (Table 2, Table S4). Cases were more likely to use toilets shared by multiple households than 364 controls (OR 1·41; 95% CI 1·11-1·79) and were less likely to live in houses with electricity (OR 365 0·72; 95% CI 0·56–0·92). Cases were also more likely to live in households with lower wealth 366 index, indicating higher level of poverty (OR 0·58; 95% CI 0·44–0·76) than controls. Although 367 likely an artifact of hygiene kit distribution that focused on case households, we found that cases 368 were more likely to live in households with soap and water available for handwashing (OR 1·86; 369 95% CI 1·40–2·49).

370

- 372
- 373
- 374
- 375

14

Table 2. Characteristics of study participants in the vaccine effectiveness analysis 24-36 months after vaccination (Study Period 2)

Characteristic	Overall,	Cases,	Controls,	P value	SMD	
	N = 1,852	N = 402	N = 1,450			
Age group at					0.179	
vaccination (years)*						
1-4	295 (15.9%)	60 (14.9%)	235 (16.2%)	Referenc		
		, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	e		
5-9	401 (21.7%)	109 (27.1%)	292 (20.1%)	0.0563		
10-19	466 (25.2%)	90 (22.4%)	376 (25.9%)	0.3003		
20-39	350 (18.9%)	67 (16.7%)	283 (19.5%)	0.0738		
40-59	245 (13.2%)	55 (13.7%)	190 (13.1%)	0.4303		
>60	95 (5.1%)	21 (5.2%)	74 (5.1%)	0.4427		
Sex		(• • _ / • /	(0.005	
Female	987 (53.3%)	215 (53.5%)	772 (53.2%)	Referenc	01000	
		210 (0010 /0)	(001270)	e		
Male	865 (46.7%)	187 (46.5%)	678 (46.8%)	0.9500		
Education		107 (10.070)	070(101070)	0.7200	0 353	
attainment**					0.000	
None or primary	190 (28.4%)	52 (41 3%)	138 (25 5%)	Referenc		
it one of primary	190 (20.170)	52 (11.576)	150 (25.570)	e		
I ower secondary	119 (17.8%)	21 (16 7%)	98 (18 1%)	0 0277		
Upper secondary	319(47.8%)	46(365%)	273(50.1%)	0.0008		
Bachelor or higher	40(60%)	7 (5 6%)	273(50.4%)	0.3492		
Occupation	+0 (0.070)	7 (3.070)	33 (0.170)	0.3472	0.113	
No work	289 (15.6%)	71 (17 7%)	218(15.0%)	Referenc	0.115	
NO WOIK	207 (15.070)	/1 (17.770)	210 (13.070)			
Preschool children	107 (10.6%)	<i>A</i> 5 (11 2%)	152 (10.5%)	0 5777		
Students	872 (14.4%)	+3(11.270) 180($//$ 8%)	6/2 (10.3%)	0.7115		
Informal work	322(44.470) 455(24.6%)	130(44.8%) 02(22.0%)	363(25.1%)	0.7113		
Soloried	+33(2+.070)	14(3.5%)	505(25.1%) 74(5.1%)	0.1405		
Missing	00 (4.0 <i>%)</i> 1	14(3.5%)	7 + (3.170)	0.0423		
Household size	$\frac{1}{70}(60.00)$	$\frac{1}{70}(53)$	70(6000)	0.2162	0.066	
median (IOP)	7.0 (0.0, 9.0)	7.0(3.3, 0.0)	7.0 (0.0, 9.0)	0.2102	0.000	
Drinking water source		9.0)			0.033	
Improved	1 037 (56 0%)	220(54.7%)	817 (56 4%)	Pafaranc	0.035	
Improved	1,037 (30.070)	220 (34.770)	817 (30.4%)	Reference		
Unimproved	814(44.004)	182 (15 304)	637 (13 60/)	0 4573		
Missing	814 (44.070) 1	162(43.3%)	0.52(43.0%)	0.4373		
Living in household	1	0	1		0 154	
Living in nousenoid					0.134	
Private	9.12(15.50/)	150(20.60/)	691(17,20/)	Deference		
Flivate	845 (45.5%)	139 (39.0%)	064 (47.2%)	Reference		
Chanad	1 000 (54 50)	242 (60 40/)	766 (57 00/)			
Silareu Toilat type	1,009 (34.3%)	243 (00.4%)	/00 (32.8%)	0.0049	0.005	
Improved	1 265 (69 20/)	767 (65 70/)	1 002 (60 20/)	Deference	0.085	
improved	1,203 (08.3%)	∠02 (0 3. 2%)	1,003 (09.2%)	Reference		

1	5	
I	J	

Unimproved	587 (31.7%)	140 (34.8%)	447 (30.8%)	e 0.1117	
Soap and water available for	881 (47.6%)	217 (54.0%)	664 (45.8%)	< 0.0001	0.164
handwashing					
Living in household with electricity	782 (42.2%)	150 (37.3%)	632 (43.6%)	0.0090	0.128
Wealth index, median	0.7 (-39.2,	-5.3 (-50.0,	2.7 (-30.9,	0.0001	0.182
(IQR) ***	36.3)	31.3)	36.5)		
Vaccination status					0.244
Not Vaccinated	1,125 (60.7%)	275 (68.4%)	850 (58.6%)	Referenc	
				e	
One Dose	525 (28.3%)	81 (20.1%)	444 (30.6%)	< 0.0001	
Two Doses	202 (10.9%)	46 (11.4%)	156 (10.8%)	0.3868	
Vaccination card available	102 (14.1%)	22 (17.9%)	80 (13.4%)	0.0252	0.125

378*Age group refers to the age on the first day of the second mass vaccination campaign round (01 October3792020). **The question about education attainment was only asked to individuals aged \geq 18 years. ***380Wealth index was multiplied by 100. The higher the wealth index the richer the household. The381distribution of age and sex of the cases and controls does not match perfectly because the number of382controls included for each case varied slightly due to enrolled controls either not meeting the eligibility383criteria (e.g., not living in Uvira during vaccination) or not recalling their vaccination status. P values are384obtained from univariable conditional logistic regression models.

386

Combining data from both study periods, 12-36 months post-vaccination, we estimated an unadjusted single-dose VE of 47.8% (95% Confidence Interval [CI] 34.6–58.4) and after adjustment for potential confounders, the VE was 48.2% (95% CI 34.8–58.8).

In SP1, 12–17 months after vaccination, we estimated an unadjusted and adjusted single-dose

391 VE of 54.4% (95% CI: 34.4–68.3) and 52.7% (95% CI: 31.4–67.4). In SP2, 24–36 months after

392 vaccination, we estimated an unadjusted VE of 43.2% (95% CI: 24.0–57.6) and an adjusted VE

393 of 45.5% (95% CI: 25.8–60.0). The adjusted VE for 1–4-year-olds was 73.5% (95% CI: 28.9–

394 90.1) in SP1 sharply declining to 33.1% (95% CI: -30.0–65.6) in SP2 and the confidence

395 intervals span the null (Table 3).

396

Table 3. Effectiveness of a single dose of oral cholera vaccine, 12-17 months and 24-36 months after vaccination campaigns.

Population	Cases	Controls	Unadjusted VE	Adjusted VE**	
	(effective n*)	(effective n [*])	(95% CI)	(95% CI)	
12-36 months after vaccination					
Overall	573 (419)	1998 (763)	47.8% (34.6–58.4)	48.2% (34.8–58.8)	
1-4 years	96 (61)	263 (129)	52.4% (22.5-70.8)	49.8% (15.6–70.2)	
≥ 5 years 463 (332) 1534 (584) 46.7% (31.8–58.4) 47.8% (32.8–59.5)					
12-17 months after vaccination (Study Period 1)					

³⁸⁵

Overall	219 (170)	704 (300)	54.4% (34.4–68.3)	52.7% (31.4-67.4)	
1-4 years	34 (23)	83 (44)	68.3% (19.6–87.5)	73.5% (28.9–90.1)	
\geq 5 years	179 (141)	568 (243)	50.9% (28.0-66.6)	46.9% (21.0-64.3)	
24-36 months after vaccination (Study Period 2)					
Overall	354 (249)	1294 (463)	43.2% (24.0–57.6)	45.5% (25.8-60.0)	
1-4 years	62 (38)	180 (85)	42.8% (-2.2-68.0)	33.1% (-30.0–65.6)	
\geq 5 years	284 (191)	966 (341)	43.4% (21.7–59.0)	48.3% (27.2–63.3)	
*				N	

399

^{*}Effective number of cases and controls is the sample size that effectively contributes to estimates of effectiveness in 400 the conditional logistic regression models. Those participants in matched case-control sets where all people have the 401 same vaccination status do not contribute to the estimates, nor do those who either do not know their vaccination 402 status or the number of doses they received. **In SP1 and in analyses combining data from both study periods, we

403 only adjusted for age as a continuous variable

404 In secondary analyses, we estimated the adjusted cumulative VE across both study periods for at

405 least one dose of kOCV to be 45.4% % (95% CI: 33.2–55.3, Table S8). We were unable to

406 reliably estimate two-dose VE due to a limited effective sample size, with post-hoc power

407 calculations suggesting we had 50.9% power to detect significant vaccine protection even when

408 combining data from both study periods and 5.1% power in young children (Table S9, Table

409 S10).

410 Discussion

We found that a single dose of Euvichol-Plus[®] kOCV provided protection against cholera for at 411

least the 36-month period post-vaccination. Our study provides unique, policy-relevant insights 412

413 into kOCV protection as we estimated single-dose effectiveness from the only available and

414 most widely used cholera vaccine today, including estimates of effectiveness for 1–4-year-olds

415 and at discrete time windows after vaccination. Our results suggest that at least in cholera

416 endemic areas like Uvira, the use of one kOCV dose may provide significant protection on the

- 417 scale of years rather than just months.
- 418

To date, one randomized trial^{17,18} and seven observational studies have included estimates of 419

one-dose protection of kOCVs.^{7-9,13-15,27} Most of these studies have been short-term estimates of 420

421 protection measured for just a few months after vaccination and showed similar levels of

422 protection to two doses on this timescale. Two notable exceptions where protection was

measured over a longer period include a randomized trial in Bangladesh and a case-control study 423

- in Haiti, both using Shanchol[®]. The Bangladesh trial was conducted for two years and estimated 424
- 425 54% (95% CI: 16 to 75) efficacy in the first year and 67% (43 to 81) in the second year post-
- vaccination among those five years and older.¹⁷ Secondary analyses from a case-control study in 426
- Haiti predicted that a single dose of kOCV (Shanchol[®]) would confer 58% (95% CI: 4 to 82%) 427
- protection at 16 months post-vaccination, with the confidence intervals including zero protection 428
- from 17-months post-vaccination and onward.¹⁴ Our results are consistent with these previous 429
- 430 studies in showing significant protection for the overall population for longer than a year, though
- 431 it is important to note that Uvira, like Haiti (at the time of the study) and Bangladesh, is endemic
- 432 for cholera so the first dose may have acted as a booster for previously exposed individuals.

17

Furthermore, it is possible that previous exposures to enterotoxigenic *Escherichia coli*, which has
been identified among diarrhoea cases in Uvira and has a antigenically similar toxin to toxigenic *V. cholerae*, could contribute to background immunity to severe disease in these settings.²⁸ More

- 436 work is needed to characterize the epidemiologic settings where one dose may provide
- 437 comparable levels of protection to the full regimen, and might include leveraging historic
- 438 incidence rates of cholera or, perhaps, population-level immunologic measures of previous
- 439 exposures.²⁹
- 440 Before this study, only one estimate of single-dose protection of a kOCV in 1–4-year-olds had
- been published. This trial, in Bangladesh, suggested that young children did not benefit from a
- 442 single dose of Shanchol[®], even during the first six months post-vaccination.^{17,18} In contrast, we
- found evidence that the population under five years old in Uvira benefited from similar levels of protection to those five and above at 12-17 months post-vaccination, however the point estimates
- 445 dropped substantially in the third year after vaccination with confidence intervals spanning the
- null. This observation is in line with studies showing similar levels of protection after natural
- 447 infection between the two age groups.³⁰ Conflicting estimates between young children and older
- 448 individuals have also been observed in kOCV studies with the full dose regimen, though there
- are only a handful of studies that present age-stratified estimates. Although most studies have
- 450 found lower effectiveness in young children, the difference in protection has been highly variable
- 451 with large uncertainty (e.g., ranging from no apparent difference in Vietnam after 10 months,³¹ to
- 452 73% lower protective efficacy among children in Bangladesh over 6 months post-vaccination¹⁸).
- 453 The contrast of our estimates with other studies could be explained by several factors including
- 454 pre-existing population immunity and season of vaccination as shown with other diseases,³²
- 455 differences both in gut microbiota composition and in prevalence of enteropathy, however, as in
- 456 all observational studies we cannot rule out confounding and selection bias.^{33,34} Additional
- 457 observational, and ideally randomized trials, would help shed further light on protection of one
- 458 dose of kOCV among young children.
- 459 While the focus of the study was to understand the direct effectiveness of kOCV, our analysis of
- 460 potential risk factors highlighted key differences between cases and matched controls. Our
- 461 results confirm the associations between cholera and markers of poverty, like using a shared
- 462 latrine, using an unimproved source for drinking water and not having electricity in the
- 463 household. While kOCV provides protection against cholera, tackling fundamental risk factors
- 464 like access to safe water and sanitation are needed to sustainably control the disease.
- 465 This study comes with several limitations. First, like many previous kOCV effectiveness studies,
- the vaccination status was self-reported,^{7,14,15} and only 29 cases (of 206 reporting to be
- 467 vaccinated) were able to provide a vaccination card. Measurements of the number of doses
- 468 received months to years after a mass vaccination campaign is prone to recall bias, particularly in
- 469 a place like Uvira where mass vaccination campaigns with different antigens are common. To
- 470 minimize biases in classification of vaccination status, we used visual aids and a series of
- 471 structured questions, and hospital and study staff reassured patients that their responses to the

18

study questions would in no way affect their care. Though enumerators were not blinded to the 472 473 vaccination status of the cases while enrolling their matched controls, the vaccine coverage 474 among controls was similar to that measured in community coverage surveys (Table S12). 475 Furthermore, sensitivity analyses restricted to only those with a vaccination card revealed similar 476 effectiveness estimates (Table S5). There were slight differences in the protocols of the case-477 control study in each study period, challenging the interpretability of the joint estimates from 478 both periods. However, in sensitivity analyses simulating similar diagnostic criteria for cases in 479 SP1 and SP2, our qualitative findings remained consistent (Table S11). The retrospective 480 recruitment of controls for cases admitted during the SP1 precluded adjustment for individual 481 and household factors that may have influenced cholera disease risk or vaccine acceptability. 482 However, such factors are unlikely to have significantly influenced the magnitude of our VE 483 estimates as we observed in the SP 2 (Table S6 and S7) and other cholera VE studies conducted elsewhere.^{7,14,15} The retrospective nature of recruitment of controls in SP1 could also have led to 484 differential recall of vaccination status among cases and their controls. Even in SP2, our VE 485 486 estimates could still be confounded by unmeasured factors. Although the number of cases under 487 five years of age was higher than in most published VE studies, our sample size in this important 488 age group was still small and led to wide confidence intervals around VE estimates (Table S2 489 and S10). Finally, we were unable to obtain reliable estimates of two dose protection partly 490 because few cases reported receipt of two doses of kOCV due to low vaccination coverage in the 491 population, and potentially because of uncertainty in the reporting of more than one dose of 492 kOCV (Tables S2, S3 S9 and Figure S2).

493

Our findings, combined with data from dose-interval studies conducted in Cameroon and Zambia^{35,36}, suggest that providing a second dose a year or more after the first could lead to better and longer lasting protection against cholera than the current two-dose series, at least among older children and adults. While more data are needed across different settings and for longer periods of time, our study extends the current evidence base on protection from a singledose of kOCV, and more specifically on protection from Euvichol-Plus[®], the most widely used cholera vaccine available today.

- 501
- 502
- 503
- 504
- 505
- 506 507
- 508
- 509

510 **Declarations**

- 19
- 511 Funding
- 512 This work was supported by the Wellcome Trust and Gavi (GAVI-RFP-2019-062).
- 513 Authors' contributions
- 514 Conceptualization: EBM, ASA, JK. Data curation: EBM, JDH, HX, CH, PMB, ASA. Formal
- analysis: EBM, ASA. Data interpretation: EBM, ASA, JK, JL, EL. Funding acquisition: ASA,
- 516 KG, OC. Investigation: EBM, PMB, CH, HX, JDH, BBR, MI, ETT, FK, TBM, AD, EL, DL, JK,
- 517 ASA. Methodology: EBM, ASA, CH, JK. Project Administration: EBM, PMB, MD, DMB,
- 518 HKM, CH, ASA, KG. Resources: PWO, JMS, DMB, AD, JK, OL. Software: EBM, JDH, HX,
- 519 ASA. Supervision: ASA, JK. Validation: EBM, ASA. Visualization EBM, ASA. Writing -
- 520 original draft EBM, ASA. Writing: review & editing: all authors.
- 521 Acknowledgements
- 522 We are thankful to Faraja Masema Lulela, Joël Faraja Zigashane Mashauri, Jean-Marie
- 523 Masugamuhanya Cirhonda, the CTCs nurses and field investigators for their support for the data
- 524 collection. We also thank the Head of the Uvira Health Zone, Dr Panzu Nimi, and the Director of
- 525 the Uvira General Referral Hospital, Dr Salomon Mashupe, for their operational and
- 526 administrative support throughout this study. We would also like to thank the MSF GIS Centre,
- 527 including Frederic Ham and Edith Rogenhofer, for their assistance with acquiring satellite
- 528 imagery data and Ahmad Alobaidi for assistance with dwelling extractions from this imagery.
- 529 Data sharing
- 530 Code and data from this study are available at
- 531 https://github.com/HopkinsIDD/uvira_onedose_ocv_ve.
- 532

533 **References**

- Deshpande A, Miller-Petrie MK, Lindstedt PA, *et al.* Mapping geographical inequalities in access to
 drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. *The Lancet Global Health* 2020; 8: e1162–85.
- 537 2 World Health Organization. Global Task Force on Cholera Control. Ending Cholera, a Global
 538 Roadmap to 2030. World Health Organization, 2017.
- Bi Q, Ferreras E, Pezzoli L, *et al.* Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 1080–8.
- Ali M, Qadri F, Kim DR, *et al.* Effectiveness of a killed whole-cell oral cholera vaccine in
 Bangladesh: further follow-up of a cluster-randomised trial. *Lancet Infect Dis* 2021; 21: 1407–14.
- 543 5 Burki T. Addressing the shortage of cholera vaccines. *Lancet Infect Dis* 2022; **22**: 1674–5.
- 6 Odevall L, Hong D, Digilio L, *et al.* The Euvichol story Development and licensure of a safe,
 effective and affordable oral cholera vaccine through global public private partnerships. *Vaccine*

- 546 2018; **36**: 6606–14.
- 547 7 Luquero FJ, Grout L, Ciglenecki I, *et al.* Use of Vibrio cholerae vaccine in an outbreak in Guinea. *N* 548 *Engl J Med* 2014; **370**: 2111–20.
- Azman AS, Parker LA, Rumunu J, *et al.* Effectiveness of one dose of oral cholera vaccine in
 response to an outbreak: a case-cohort study. *Lancet Glob Health* 2016; 4: e856–63.
- Grandesso F, Kasambara W, Page A-L, *et al.* Effectiveness of oral cholera vaccine in preventing
 cholera among fishermen in Lake Chilwa, Malawi: A case-control study. *Vaccine* 2019; **37**: 3668–
 76.
- Sialubanje C, Kapina M, Chewe O, *et al.* Effectiveness of two doses of Euvichol-plus oral cholera
 vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia. *BMJ Open* 2022; **12**: e066945.
- World Health Organization. Weekly epidemiological record. World Health Organization, 22
 SEPTEMBER 2023, 98th YEAR https://iris.who.int/handle/10665/372986 (accessed Oct 17, 2023).
- World Health Organization. Shortage of cholera vaccines leads to temporary suspension of two-dose strategy, as cases rise worldwide. 2022; published online Oct 19. https://www.who.int/news/item/19-10-2022-shortage-of-cholera-vaccines-leads-to-temporary-suspension-of-two-dose-strategy-as-cases-rise-worldwide (accessed March 24, 2023).
- 563 13 Khatib AM, Ali M, von Seidlein L, *et al.* Effectiveness of an oral cholera vaccine in Zanzibar:
 564 findings from a mass vaccination campaign and observational cohort study. *Lancet Infect Dis* 2012;
 565 12: 837–44.
- Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term effectiveness of one
 and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control
 study. *Lancet Glob Health* 2018; 6: e1028–35.
- 569 15 Ferreras E, Blake A, Chewe O, *et al.* Alternative observational designs to estimate the effectiveness
 570 of one dose of oral cholera vaccine in Lusaka, Zambia. *Epidemiol Infect* 2020; 148: e78.
- Ivers LC, Hilaire IJ, Teng JE, *et al.* Effectiveness of reactive oral cholera vaccination in rural Haiti: a
 case-control study and bias-indicator analysis. *Lancet Glob Health* 2015; 3: e162–8.
- 573 17 Qadri F, Ali M, Lynch J, *et al.* Efficacy of a single-dose regimen of inactivated whole-cell oral
 574 cholera vaccine: results from 2 years of follow-up of a randomised trial. *Lancet Infect Dis* 2018; 18:
 575 666–74.
- 576 18 Qadri F, Wierzba TF, Ali M, *et al.* Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in
 577 Bangladesh. *N Engl J Med* 2016; **374**: 1723–32.
- 578 19 Bugeme PM, Xu H, Hutchins C, *et al.* Cholera deaths during outbreaks in Uvira, Eastern Democratic
 579 Republic of Congo, September 2021-January 2023. bioRxiv. 2023; published online June 3.
 580 DOI:10.1101/2023.05.26.23290528.
- Schyns C, Fossa A, Mutombo-Nfenda, *et al.* Cholera in Eastern Zaire, 1978. *Ann Soc Belg Med Trop* 1979; **59**: 391–400.
- 583 21 Jeandron A. Tap water access and its relationship with cholera and other diarrhoeal diseases in an

584 585		urban, cholera-endemic setting in the Democratic Republic of the Congo. 2020; published online Dec 12. DOI:10.17037/PUBS.04659288.
586 587	22	Jeandron A, Cumming O, Kapepula L, Cousens S. Predicting quality and quantity of water used by urban households based on tap water service. <i>npj Clean Water</i> 2019; 2 : 1–9.
588 589 590	23	Gaiffe M, Dross C, Malembaka EB, Ross I, Cumming O, Gallandat K. A fuzzy inference-based index for piped water supply service quality in a complex, low-income urban setting. <i>Water Res</i> 2023; : 120316.
591 592 593	24	Gallandat K, Macdougall A, Jeandron A, <i>et al.</i> 1 Improved water supply infrastructure to reduce acute diarrhoeal diseases and 2 cholera in Uvira, Democratic Republic of the Congo: results and lessons learned 3 from a pragmatic trial. https://osf.io/na47d/download (accessed July 23, 2023).
594 595 596	25	Debes AK, Ateudjieu J, Guenou E, <i>et al.</i> Clinical and Environmental Surveillance for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North Region of Cameroon. <i>Am J Trop Med Hyg</i> 2016; 94 : 537–43.
597 598	26	Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. <i>Biom J</i> 2008; 50 : 346–63.
599 600	27	Wierzba TF, Kar SK, Mogasale VV, <i>et al.</i> Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India. <i>Vaccine</i> 2015; 33 : 2463–9.
601 602 603	28	Clemens JD, Sack DA, Harris JR, <i>et al.</i> Cross-Protection by B Subunit-Whole Cell Cholera Vaccine Against Diarrhea Associated with Heat-Labile Toxin-Producing Enterotoxigenic Escherichia coli: Results of a Large-Scale Field Trial. <i>J Infect Dis</i> 1988; 158 : 372–7.
604 605	29	Azman AS, Lessler J, Luquero FJ, <i>et al.</i> Estimating cholera incidence with cross-sectional serology. <i>Sci Transl Med</i> 2019; 11 . DOI:10.1126/scitranslmed.aau6242.
606 607	30	Ali M, Emch M, Park JK, Yunus M, Clemens J. Natural Cholera Infection–Derived Immunity in an Endemic Setting. <i>J Infect Dis</i> 2011; 204 : 912–8.
608 609	31	Trach DD, Clemens JD, Ke NT, <i>et al.</i> Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. <i>Lancet</i> 1997; 349 : 231–5.
610 611	32	Moore SE, Collinson AC, Fulford AJC, <i>et al.</i> Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. <i>Trop Med Int Health</i> 2006; 11 : 1529–41.
612 613	33	Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. <i>Clin Microbiol Rev</i> 2019; 32 . DOI:10.1128/CMR.00084-18.
614 615	34	Porras AM, Shi Q, Zhou H, <i>et al.</i> Geographic differences in gut microbiota composition impact susceptibility to enteric infection. <i>Cell Rep</i> 2021; 36 : 109457.
616 617	35	Mwaba J, Chisenga CC, Xiao S, <i>et al.</i> Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia. <i>Vaccine</i> 2021; 39 : 4516–23.
618 619 620	36	Ateudjieu J, Sack DA, Nafack SS, <i>et al.</i> An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon. <i>Am J Trop Med Hyg</i> 2022; 107 : 974–83.